Development of CDD-0102 as a selective M1 agonist for the treatment of Alzheimer's disease

Drug Development Research

Volumn 57, Issue 4, 2002, Pages 200-213

  Messer Jr , William S ^a   Bachmann, Kenneth A ^a   Dockery, Colleen ^a   El Assadi, Afif A ^a   Hassoun, Ezdihar ^a   Haupt, Nicola ^a   Tang, Bin ^a   Li, Xuemei ^a  

^a MEDICAL COLLEGE OF OHIO   (United States)

Author keywords

192 IgG saporin; Memory; Muscarinic receptors

Indexed keywords

ALPHA SECRETASE; AMYLOID PRECURSOR PROTEIN; ATROPINE; CDD 0102; CHOLINE ACETYLTRANSFERASE; IMMUNOGLOBULIN G; MUSCARINIC M1 RECEPTOR AGONIST; SAPORIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; XANOMELINE;

ACUTE TOXICITY; ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD BRAIN BARRIER; CHO CELL; CHOLINERGIC ACTIVITY; COGNITION; COMPARTMENT MODEL; CONTROLLED STUDY; DIARRHEA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PENETRATION; DRUG PROTEIN BINDING; FOREBRAIN; HYPERSALIVATION; LD 50; MALE; MAZE TEST; MEMORY DISORDER; MOUSE; NONHUMAN; RAT;

EID: 0037002825     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10153     Document Type: Article

References (57)

1. Bartus RT. 2000. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol 163:495-529.
2. Bartus RT, Dean RL 3rd, Beer B, Lippa AS. 1982. The cholinergic hypothesis of geriatric memory dysfunction. Science 217:408-414.
3. Bodiek NC, Offen WW, Levey AI, Cutler NR, Gauthier SG, Satlin A, Shannon HE, Tollefson GD, Rasmussen K, Bymaster FP, Hurley DJ, Potter WZ, Paul SM. 1997. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol 34:465-473.
4. Bonner TI. 1989. The molecular basis of muscarinic receptor diversity. Trends Neurosci 12:148-151.
5. Buxbaum JD, Ruefli AA, Parker CA, Cypess AM, Greengard P. 1994. Calcium regulates processing of the Alzheimer amyloid protein precursor in a protein kinase C-independent manner. Proc Natl Acad Sci USA 91:4489-4493.
6. Bymaster FP, Heath I, Hendrix JC, Shannon HE. 1993. Comparative behavioral and neurochemical activities of cholinergic antagonists in rats. J Pharmacol Exp Ther 267:16-24.
7. Bymaster FP, Wong DT, Mitch CH, Ward JS, Calligaro DO, Schoepp DD, Shannon HE, Sheardown MJ, Olesen PH, Suzdak PD, et al. 1994. Neurochemical effects of the M1 muscarinic agonist xanomeline (LY246708/NNC1-0232). J Pharmacol Exp Ther 269:282-289.
8. Bymaster FP, Wong DT, Whitesitt CA, Shannon HE, DeLapp N, Ward JS, Calligaro DO, Shipley LA, Buellke-Sam JL, Bodick NC, Farde L, Sheardown MJ, Olesen PH, Hansen KT, Suzdak PD, Swedberg MDB, Sauerberg P, Mitch CH. 1997. Xanomeline: a selective muscarinic agonist for the treatment of Alzheimer's disease. Drug Dev Res 40:158-170.
9. Caulfield MP, Birdsall NJ. 1998. International Union of Pharmacology. XVII. Classification of muscarinic acetylcholine receptors. Pharmacol Rev 50:279-290.
10. Caulfield MP, Higgins GA, Straughan DW. 1983. Central administration of the muscarinic receptor subtype-selective antagonist pirenzepine selectively impairs passive avoidance learning in the mouse. J Pharm Pharmacol 35:131-132.
11. Coyle JT, Price DL, DeLong MR. 1983. Alzheimer's disease: a disorder of cortical cholinergic innervation. Science 219:1184-1190.
12. Davies P. 1979. Neurotransmitter-related enzymes in senile dementia of the Alzheimer type. Brain Res 171:319-327.
13. Doods HN, Mathy MJ, Davidesko D, van Charldorp KJ, de Jonge A, van Zwieten PA. 1987. Selectivity of muscarinic antagonists in radioligand and in vivo experiments for the putative M1, M2 and M3 receptors. J Pharmacol Exp Ther 242:257-262.
14. Dunbar PG, Durant GJ, Fang Z, Abuh YF, el-Assadi AA, Ngur DO, Periyasamy S, Hoss WP, Messer WS Jr. 1993. Design, synthesis, and neurochemical evaluation of 5-(3-alkyl-1,2,4-oxadiazol-5-yl)-1,4,5,6-tetrahydropyrimidines as Mi muscarinic receptor agonists. J Med Chem 36:842-847.
15. Eckols K, Bymaster FP, Mitch CH, Shannon HE, Ward JS, DeLapp NW. 1995. The muscarinic M1 agonist xanomeline increases soluble amyloid precursor protein release from Chinese hamster ovary-m1 cells. Life Sci 57:1183-1190.
16. Ferrari-DiLeo G, Mash DC, Flynn DD. 1995. Attenuation of muscarinic receptor-G-protein interaction in Alzheimer disease. Mol Chem Neuropathol 24:69-91.
17. Flynn DD, Ferrari-DiLeo G, Levey AI, Mash DC. 1995a. Differential alterations in muscarinic receptor subtypes in Alzheimer's disease: Implications for cholinergic-based therapies. Life Sci 56:869-876.
18. Flynn DD, Ferrari-DiLeo G, Mash DC, Level, AI. 1995b. Differential regulation of molecular subtypes of muscarinic receptors in Alzheimer's disease. J Neurochem 64:1888-1891.
19. Fonnum F. 1975. A rapid radiochemical method for the determination of choline acetyltransferase. J Neurochem 24:407-409.
20. Forster GL, Yeomans JS, Takeuchi J, Blaha CD. 2002. M5 muscarinic receptors are required for prolonged accumbal dopamine release after electrical stimulation of the pons in mice. J Neurosci 22:RC190.
21. Hagan JJ, Jansen JH, Broekkamp CL. 1987. Blockade of spatial learning by the M1 muscarinic antagonist pirenzepine. Psychopharmacology 93:470-476.
22. Hammer R, Berrie CP, Birdsall NJ, Burgen AS, Hulme EC. 1980. Pirenzepine distinguishes between different subclasses of muscarinic receptors. Nature 283:90-92.
23. Hammer R, Giraldo E, Schiavi GB, Monferini E, Ladinsky H. 1986. Binding profile of a novel cardioselective muscarine receptor antagonist, AF-DK 116, to membranes of peripheral tissues and brain in the rat. Life Sci 38:1653-1662.
24. Hersch SM, Gutekunst CA, Rees HD, Heilman CJ, Levey AI. 1994. Distribution of m1-m4 muscarinic receptor proteins in the rat striatum: light and electron microscopic immunocytochemistry using subtype-specific antibodies. J Neurosci 14:3351-3363.
25. Hock C, Maddalena A, Heuser I, Naber D, Oertel W, von der Kammer H, Wienrich M, Deng M, Growdon JH, Nitsch RM. 2000. Treatment with the selective muscarinic agonist talsaclidine decreases cerebrospinal fluid levels of Aβ in patients with Alzheimer's disease. Soc Neurosci Abstr p 679.613.
26. Holley LA, Wiley RG, Lappi DA, Sarter M. 1994. Cortical cholinergic deafferentation following the intracortical infusion of 192 IgG-saporin: a quantitative histochemical study. Brain Res 663:277-286.
27. Hoss W, Woodruff JM, Ellerbrock BR, Periyasamy S, Ghodsi-Hovsepian S, Stibbe J, Bohnett M, Messer WS Jr. 1990. Biochemical and behavioral responses of pilocarpine at muscarinic receptor subtypes in the CNS. Comparison with receptor binding and low-energy conformations. Brain Res 533:232-238.
28. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
29. Markwell MA, Haas SM, Bieber LL, Tolbert NE. 1978. A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem 87:206-210.
30. Mash DC, Flynn DD, Potter LT. 1985. Loss of M2 muscarine receptors in the cerebral cortex in Alzheimer's disease and experimental cholinergic denervation. Science 228:1115-1117.
31. McDonald MP, Overmier JB. 1998. Present imperfect: a critical review of animal models of the mnemonic impairments in Alzheimer's disease. Neurosci Biobehav Rev 22:99-120.
32. Messer WS, Jr., Thomas GJ, Hoss W. 1987. Selectivity of pirenzepine in the central nervous system. Ii. Differential effects of pirenzepine and seopolamine on performance of a representational memory task. Brain Res 407:37-45.
33. 1 muscarinic receptors in representational memory. Neurosci Lett 116:184-189.
34. Messer WS Jr, Stibbe JR, Bohnett M. 1991. Involvement of the septohippocampal cholinergic system in representational memory. Brain Res 564:66-72.
35. 1 receptors. Bioorg Med Chem Lett 2:781-786.
36. 1 muscarinic receptors in brain. Drug Dev Res 40:171-184.
37. Messer WS Jr, Abuh YF, Liu Y, Periyasamy S, Ngur DO, Edgar MA, El-Assadi AA, Sbeih S, Dunbar PG, Roknich S, Rho T, Fang Z, Ojo B, Zhang H, Huzl JJ 3rd, Nagy PI. 1997b. Synthesis and biological characterization of 1,4,5,6-tetrahydropyrimidine and 2-amino-3,4,5,6-tetrahydropyridine derivatives as selective m1 agonists. J Med Chem 40:1230-1246.
38. Murga C, Laguinge L, Wetzker R, Cuadrado A, Gutkind JS. 1998. Activation of Akt/protein kinase B by G protein-coupled receptors. A role for alpha and beta gamma subunits of heterotrimeric G proteins acting through phosphatidylinositol-3-OH kinase gamma. J Biol Chem 273:19080-19085.
39. Murga C, Fukuhara S, Gutkind JS. 2000. A novel role for phosphatidylinositol 3-kinase beta in signaling from G proteincoupled receptors to Akt. J Biol Chem 275:12069-12073.
40. Nitsch RM, Slack BE, Wurtman RJ, Growdon JH. 1992. Release of Alzheimer amyloid precursor derivatives stimulated by activation of muscarinic acetylcholine receptors. Science 258:304-307.
41. Nitsch RM, Deng M, Tennis M, Schoenfeld D, Growdon JH. 2000. The selective muscarinic M1 agonist AF102B decreases levels of total a[beta] in cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol 48:913-918.
42. Pearce BD, Potter LT. 1991. Coupling of ml muscarinic receptors to G protein in Alzheimer disease. Alzheimer Dis Assoc Disord 5:163-172.
43. Sauerberg P, Olesen PH, Nielsen S, Treppendahl S, Sheardown MJ, Honore T, Mitch CH, Ward JS, Pike AJ, Bymaster FP, et al. 1992. Novel functional M1 selective muscarinic agonists. Synthesis and structure-activity relationships of 3-(1,2,5-thiadiazolyl)-1,2,5,6-tetrahydro-1-methylpyridines. J Med Chem 35:2274-2283.
44. Shannon HE, Bymaster FP, Calligaro DO, Greenwood B, Mitch CH, Sawyer BD, Ward JS, Wong DT, Olesen PH, Sheardown MJ, et al. 1994. Xanomeline: a novel muscarinic receptor agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther 269:271-281.
45. Shimohama S, Taniguchi T, Fujiwara M, Kameyama M. 1986. Changes in nicotinic and muscarinic cholinergic receptors in Alzheimer-type dementia. J Neurochem 46:288-293.
46. Soininen H, Kosunen O, Helisalmi S, Mannermaa A, Paljarvi L, Talasniemi S, Ryynanen M, Riekkinen P Sr. 1995. A severe loss of choline acetyltransferase in the frontal cortex of Alzheimer patients carrying apolipoprotein epsilon 4 allele. Neurosci Lett 187:79-82.
47. Thomas GJ, Gash DM. 1986. Differential effects of posterior septal lesions on dispositional and representational memory. Behav Neurosci 100:712-719.
48. Thomas GJ, Spafford PS. 1984. Deficits for representational memory induced by septal and cortical lesions (singly and combined) in rats. Behav Neurosci 98:394-404.
49. Walsh TJ, Kelly RM, Dougherty KD, Stackman RW, Wiley RG, Kutscher CL. 1995. Behavioral and neurobiological alterations induced by the immunotoxin 192-IgG-saporin: cholinergic and non-cholinergic effects following i.c.v. injection. Brain Res 702:233-245.
50. Walsh TJ, Herzog CD, Gandhi C, Stackman RW, Wiley RG. 1996. Injection of IgG 192-saporin into the medial septum produces cholinergic hypofunction and dose-dependent working memory deficits. Brain Res 726:69-79.
51. Weihl CC, Ghadge GD, Kennedy SG, Hay N, Miller RJ, Roos RP. 1999. Mutant presenilin-1 induces apoptosis and downregulates Akt/PKB. J Neurosci 19:5360-5369.
52. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR. 1982. Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215:1237-1239.
53. Widzowski DV, Bialobok P, Kucera KE, Mihut R, Sitar S, Knowles M, Stagnitto M, Howell A, McCreedy SA, Machulskis AC, Zongrone J, Gordon J, Marler M, Wu ESC, Mullen GB, Triggle DJ, Blosser JC. 1997. Development of a pharmacological profile for muscarinic agonists. Drug Dev Res 40:117-132.
54. Wolf BA, Wertkin AM, Jolly YC, Yasuda RP, Wolfe BB, Konrad RJ, Manning D, Ravi S, Williamson JR, Lee VM. 1995. Muscarinic regulation of Alzheimer's disease amyloid precursor protein secretion and amyloid beta-protein production in human neuronal NT2N cells. J Biol Chem 270:4916-4922.
55. Wrenn CC, Lappi DA, Wiley RG. 1999. Threshold relationship between lesion extent of the cholinergic basal forebrain in the rat and working memory impairment in the radial maze. Brain Res 847:284-298.
56. Yasuda RP, Ciesla W, Flores LR, Wall SJ, Li M, Satkus SA, Weisstein JS, Spagnola BV, Wolfe BB. 1993. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149-157.
57. Zhang W, Basile AS, Gomeza J, Volpicelli LA, Levey AI, Wess J. 2002. Characterization of central inhibitory muscarinic autoreceptors by the use of muscarinic acetylcholine receptor knockout mice. J Neurosci 22:1709-1717.